Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Lenvatinib in Advanced RCC
NCT05262413Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in renal cell carcinoma (RCC), sponsored by Qilu Pharmaceutical. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
QL1706
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05262413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262413.